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Phage-inducible chromosomal islands (PICIs) are a widespread family of mobile genetic elements, which have an important role in
bacterial pathogenesis. These elements mobilize among bacterial species at extremely high frequencies, representing an attractive
tool for the delivery of synthetic genes. However, tools for their genetic manipulation are limited and timing consuming. Here,
we have adapted a synthetic biology approach for rapidly editing of PICIs in Saccharomyces cerevisiae based on their ability to
excise and integrate into the bacterial chromosome of their cognate host species. As proof of concept, we engineered several
PICIs from Staphylococcus aureus and Escherichia coli and validated this methodology for the study of the biology of these
elements by generating multiple and simultaneous mutations in different PICI genes. For biotechnological purposes, we also
synthetically constructed PICIs as Trojan horses to deliver different CRISPR-Cas9 systems designed to either cure plasmids or
eliminate cells carrying the targeted genes. Our results demonstrate that the strategy developed here can be employed
universally to study PICIs and enable new approaches for diagnosis and treatment of bacterial diseases.
1. Introduction
In recent years, we have extensively studied the biology and
genetics of a novel class of very widespread, chromosomally
located, mobile elements, the phage-inducible chromosomal
islands (PICIs) [1–3]. PICIs are phage satellites, intimately
related to certain temperate (helper) phages, whose life cycles
they parasitize. Following infection by a phage or SOS induc-
tion of a prophage, PICI genomes excise from the bacterial
chromosome, using PICI-encoded integrases (int) and exci-
sion functions (xis) [3–5], they replicate extensively using
their own replicons [3, 6] and are efficiently packaged into
infectious particles composed of phage virion proteins [3,
7–9]. This preferential packaging occurs at the expense of
helper phage packaging, which is blocked by the PICIs using
several elegant and sophisticated strategies of molecular
piracy [2, 10–12].
In addition to their fascinating life cycle, PICIs have
raised curiosity in the scientific community because of their
importance as key players driving bacterial evolution and vir-
ulence. Of note is the fact that PICIs are clinically important
because they carry and disseminate virulence and antibiotic-
resistance genes [13]. For example, the prototypical and best-
characterized members of the PICI family, the Staphylococcus
aureus pathogenicity islands (SaPIs), carry and spread toxin-
encoding genes between bacteria, including one that can
cause toxic shock syndrome in humans [14]. Interestingly,
it has been recently proposed that these elements could be
used as an alternative to phages and antibiotics to combat
S. aureus infections [15].
While the interest in characterizing PICIs is clear, their
study has been partially limited by the lack of efficient tools
to easily manipulate these elements in different species. Cur-
rently, manipulation of the PICI genomes requires multiple
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steps including cloning of the desired constructs in Escheri-
chia coli using shuttle vectors, which will be introduced into
the specific strains carrying the PICIs. Then, the genes of
interest will be introduced or deleted from the PICIs by dou-
ble crossover [3, 12, 16–18].
In order to solve this problem, we explored the possibility
that some of the methods currently used to manipulate
phages could be easily adapted to engineer PICIs [19].
Recombinant E. coli phage genomes have been successfully
assembled in yeast using a yeast artificial chromosome [20].
This process is called rebooting, where reactivation of a syn-
thetic phage genome takes place in the appropriate host cell
after being assembled in yeast or in vitro. To do that, the
authors amplified the entire phage genome of interest in dif-
ferent PCR fragments that partially overlap (>30 bp overlap-
ping). The first and last fragments of the phage genome are
amplified with primers that carry “arms” that have homology
with a yeast artificial chromosome (YAC) fragment, which
may be obtained by PCR or any other suitable method. The
different fragments are (including the viral genome and the
YAC) transformed into yeast, and gap repair joins each frag-
ment to the adjacent one templated by the homology regions
at the end of each fragment, yielding a full phage genome
cloned into a replicative yeast plasmid. The generated YAC-
phage genome is purified from the yeast and transformed
into E. coli, where the synthetic phage will replicate. Then,
the cells are lysed with chloroform, and supernatants con-
taining the infective phage particles are mixed with overnight
cultures of natural-host bacteria for each phage, to promote
phage replication and plaque formation. However, PICIs
cannot be reactivated in the same way as the phages because
they do not produce functional infective particles in the
absence of their helper phage. This difference in their life
cycle makes some of the strategies used to engineer phages,
including the use of bacterial L-forms [21], not applicable
to reboot PICIs. Another limitation is that PICI-encoded
integrases are quite promiscuous facilitating integration of
these elements in aberrant places in the absence of their cog-
nate attB sites [22]. Thus, a circular YAC-PICI element con-
taining the structure of a packaged PICI would probably
promote the integration of this element into the yeast
genome. An additional obstacle that should be tackled relates
to the fact that while the yeast-based approach allows rapid
phage genome engineering of lytic E. coli phages, its use with
other classes of mobile genetic elements, or with phages from
Gram-positive bacteria, has not yet been demonstrated.
We hypothesized, however, that it should be possible to
assemble synthetic PICI genomes into the YAC, followed
by a subsequent transfer and reactivation of the YAC-PICI
DNA directly into those species of interest. To do this, and
to solve the aforementioned problems, we designed a strategy
in which the PICIs will be assembled in the YAC mirroring
the structure they have when they are integrated into the bac-
terial chromosome, rather than the genomic structure they
have when they are packaged in infective particles. We
hypothesized that this strategy would avoid aberrant YAC-
PICI integration in the yeast while, after transformation of
the YAC-PICI DNA into the species of interest, this gener-
ated genomic structure will allow excision of the element
from the YAC and the subsequent integration of the PICI
into the bacterial chromosome (Figure 1). To facilitate this,
the YAC contains not just the PICI genome but also the chro-
mosomal DNA flanking the PICI in the bacterial genome (see
scheme in Figure S1). If true, this strategy will significantly
impact the field by providing a new method to easily
manipulate PICIs from different species, including those
from relevant Gram-positive and Gram-negative pathogens.
2. Materials and Methods
2.1. Bacterial Strains and Growth Conditions. All strains used
in this study are listed in Table S1. Single colonies from the
desired strain were grown overnight in the appropriate media
supplemented with antibiotics, where required. Bacterial cells
were stored as 15% (v/v) glycerol (Fisher Scientific) stocks
at -80°C from overnight cultures. S. aureus strains were
routinely grown on tryptic soy agar (TSA) or in tryptic soy
broth (TSB) (Oxoid) in an orbital shaker at 80 or 120 rpm
at 30°C or 37° C, respectively. Antibiotics and chromogenic
substrates used included erythromycin (10μgml-1, Sigma-
Aldrich), tetracycline (3μgml-1, Sigma-Aldrich), and X-gal
(80μgml-1, Roche). E. coli strains were routinely grown on
Luria-Bertani (LB, Sigma-Aldrich) agar (LBA) plates or in LB
liquid medium grown in an orbital shaker at 80 or 120 rpm
at 30°C or 37 ° C, respectively. Antibiotics (Sigma-Aldrich)
and chromogenic substrates used to maintain transformed
plasmids and grow selectively were ampicillin (100μgml-1
Sigma-Aldrich), chloramphenicol (20μgml-1 Sigma-Aldrich),
and tetracycline (20μgml-1 Sigma-Aldrich).
2.2. Plasmid Construction. KAPA High Fidelity DNA poly-
merase (Sigma-Aldrich) was used to obtain PCR products
for use in cloning. PCR products were purified directly from
the PCR reaction mix using the QIAquick® PCR Purification
Kit (Qiagen), following manufacturer’s instructions. DNA
concentrations were established using a Nanodrop 1000
spectrophotometer (Thermo Fisher Scientific).
The plasmids used in this study (Table S2) were
constructed by cloning PCR products, amplified with the
oligonucleotides listed in Table S3 (Sigma-Aldrich), into the
appropriate vectors [23]. The cloned plasmids were verified
by Sanger sequencing (Eurofins Genomics). Plasmids used
for PICI rebooting were transformed into the host cells by
following the protocol described by Monk et al. [24]. The
Pcad-cas9-rsaE and Pcad-cas9-∅ sequences were obtained
from pFREE [25] and pCN51 [26]; cas9-mecA and cas9-∅
sequences were obtained from pRIC10 and pRIC13; Pbla-
gfpmut2 sequence was obtained from pCN68 [26]; Pbla-
bgaB sequence was obtained from pMAD [17]; Ptet-cas9-
ndm1 and Ptet-cas9-∅ were obtained from pRC319-∅
and pRC319 [27].
2.3. Yeast Assembly. Cells of S. cerevisiae strain BY23849 were
inoculated into 20ml of 2X YPAD media (Sigma-Aldrich)
and incubate at 30°C, 210RPM overnight. On a 250ml flask
with 50ml of 2X YPAD, 5ml of overnight culture were added
and incubated at 30 °C, 210 RPM until the cell density has
reached 2:0 × 107 cells ml-1 or OD600 1.0. This should make
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up to 12 transformations but can be scaled up. For each trans-
formation, 3-4ml of cells were harvested by centrifugation at
max speed (>6,000 × g) for 30 sec. Cells were resuspended
and washed twice in 0.1M lithium acetate (Sigma-Aldrich)
(LiAC) and centrifuged at max speed for 30 sec.
For each pellet, 260μl of PEG 50% (Fisher Scientific)w/v,
36μl of 1.0M LiAC (Sigma-Aldrich), and 50μl of salmon
sperm single-stranded DNA (2mgml-1 Sigma Aldrich) were
added. Carrier DNA needs to be at room temperature for
5min prior to use. Following this, 14μl of a mixture of
DNA and MilliQ gradient H2O containing YAC and PCR
fragments (~250ng of YAC PCR and ~500ng of each PCR
fragment) were added to the transformation mixture. Note
that the volume can exceed the 14μl mentioned above if
the concentration of fragments is lower than 500ngμl-1. Cells
can also be frozen and stored using storing solution (5% glyc-
erol Fisher Scientific, 10% DMSO Sigma-Aldrich) and incu-
bating them in a slow freezing container for 4 h at -80°C.
Cells were vortexed vigorously to resuspend the pellet
and then incubated at 42°C for 45min. Cells need to be mixed
periodically. Cells were then centrifuged at >6,000 × g for
3min, and the supernatant was removed. Finally, 200μl of
MilliQ grade water was added carefully to resuspend the pel-
let and cells subsequently plated onto appropriate synthetic
dropout media (SD) plates (see supplementary material and
methods for more details). Plates were incubated at 30°C
for 3 days.
2.4. Yeast-Colony PCR and Plasmid Extraction. Between 10
and 15 colonies were restreaked onto SD media plates and
incubated at 30°C overnight. Yeast colony PCRs were per-
formed using primers from one region to the other in order
to generate a product that proves the gap repair between
two PCR fragments. From each isolated colony, a smear
was added with a 10μl tip onto an Eppendorf microfuge
tube and microwaved for 5min at full power placing the
tubes at the edge of the microwave plate. After this, tubes
were left on ice for 5min and the PCR reaction mix was
added to each sample.
Once positive colonies were identified, these were inocu-
lated into 20ml of SD media in a 100ml flask and incubated
for 48 h at 30°C with shaking at 210 rpm. To harvest the plas-
mids, cells were spun down at >6,000 × g for 5min, resus-
pended into 500μl of lyticase buffer (1M sorbitol Fisher
Scientific and 0.1M Na2EDTA pH7.5 Thermo-Fisher), and
split into two tubes. Then 20μl l of lyticase solution (Lyticase
from Arthrobacter luteus 2.5μgμl-1 Sigma-Aldrich, 1.2M
sorbitol Thermo-Fisher and 10mM sodium phosphate
pH7.5 Fisher Scientific) was added, and samples were incu-
bated for 2 h at 37°C and 120 rpm. After incubation, samples
were centrifuged at >6,000 × g for 3min, and plasmids were
harvested using Qiagen miniprep extraction kit following the
manufacturer’s protocol.
2.5. PICI Rebooting. For PICI rebooting, competent cells
were transformed with plasmids (Table S2) and after elec-
troporation incubated for 2 h at 37°C and 120 rpm.
Generally, >1μg of plasmid DNA is used for a successful
transformation in E. coli and >2μg for S. aureus electro-
competent cells [16, 24].
2.6. Induction and Titration. For S. aureus, an overnight cul-
ture in TSB (Sigma-Aldrich) was diluted 1 : 50 in TSB and
cultured in a shaking incubator at 37°C and 120 rpm until
YAC
PCR products
PICI fragments
Transformation
Gap-repair cloning
Plasmid extraction
Approx. 6 kb
E. coli
S. aureus
PICI excises from YACPICI integrates into att BPICI induction
Gram-negative PICI
Gram-positive PICI
24 h 
≈ 0.6 𝜇g or 0.8 𝜇g
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Synthetic PICI in YAC
Yeast colony PCR to confirm fragments
Figure 1: PICI assembly and rebooting workflow. For the assembly of a YAC-PICI, a PCR fragment containing the yeast replicon and
selection marker from pAUR112 is required. Additionally, PCR products containing the PICI regions to assemble in the YAC vector by
gap-repair cloning are used. All PCR fragments present, at their ends, partially overlapping regions. The final product will mirror the PICI
structure in the chromosome. YAC-PICI DNA is extracted from the yeast and directly transformed into competent cells of the host
bacterium. Then, the PICI excises from the YAC and integrates into its corresponding attachment site located on the chromosome. The
whole process can be followed through the selective marker present in the island. For rebooting the island, the induction of its cognate
helper phage is needed.
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0.2-0.3 OD540. PICIs and phages were then induced by add-
ing mitomycin C (1mgml-1) at a final concentration of
2μgml-1. For E. coli PICIs and phages, an overnight culture
in LB media (Sigma-Aldrich) was diluted in 1 : 50 and cul-
tured in a shaking incubator at 37°C and 150 rpm until
0.15-0.17 OD600. PICIs and phages were then induced by
adding mitomycin C (1mgml-1 Sigma-Aldrich) at a final
concentration of 1μgml-1. The cultures were incubated at
30°C and 80 rpm for 3-4 hours. Generally, cell lysis occurred
4-5 h postinduction. To store lysates, the solution was filtered
through a 0.2μm filter (Minisart® single use syringe filter
unit, hydrophilic and nonpyrogenic, Sartorious Stedim Bio-
tech), and the phage stock was stored at 4°C or -80°C.
The PICI derivatives used in this work contained a tetM,
ermC, or cat antibiotic resistance cassette. These markers
allow for the selection of the PICI, on media supplemented
with the appropriate antibiotic. Transduction titering assays
were performed in S. aureus strain RN4220 as recipient for
all SaPIs and in E. coli using strain 594 as a recipient for the
EcCICFT073 islands. A 1 : 50 dilution of an overnight culture
was prepared and grown until OD540 or OD600 = 1:4 was
reached. Strains were infected using 1ml of the recipient cul-
ture with the addition of 100μl of phage lysate serial dilu-
tions, prepared in phage buffer, and cultures were
supplemented with CaCl2 to a final concentration of 5mM
before incubation for 30min at 37°C. This incubation allows
the PICI to infect the acceptor strain. After incubation, 3ml
of top agar (media +3% agar) at 55°C was added and imme-
diately poured over the surface of a plate containing selective
antibiotic and necessary nutrients. For S. aureus, TSA plates
with antibiotics were used for the selective culture of the suc-
cessfully transduced bacteria with SaPIs. For E. coli, LB plates
with antibiotics were used for the selective culture of the suc-
cessfully transduced bacteria with Gram-negative PICIs.
After the top agar had solidified (15-20min), the plates were
flipped and incubated at 37°C for 24 h. The number of colo-
nies formed was counted, and the colony-forming units
(CFU per ml) were calculated.
An overnight culture of the appropriate recipient strain
was diluted 1 : 50 with fresh medium and grown until 0.3-0.4
OD540 or OD600. The phage lysate was set-up as serial dilutions
using phage buffer (1mM NaCl Fisher Scientific, 0.05M Tris
pH7.8 Fisher Scientific, 1mM MgSO4, 4mM CaCl2 Fisher
Scientific). In a sterile test tube, 100μl of the recipient cells
was added with 100μl of serial dilutions of phage lysates in
phage buffer and incubated at room temperature for 10min.
Then, 3ml of Phage Top Agar (PTA) (20g l-1 nutrient broth
n°2, Oxoid; 3.5 g l-1 agar; 10mM CaCl2 Fisher Scientific) at
55°C was added to the tube and immediately poured over the
surface of a Phage Base Plate (PB) (20 g l-1 nutrient broth
n°2, Oxoid; 7 g l-1 agar; 10mM CaCl2 Fisher Scientific). When
the top agar was solidified after 15-20min, the plates were
flipped and incubated at 37°C overnight. The PBA plates were
left at room temperature to dry before being incubated at 37°C
for 24h. The number of plaques formed was counted, and the
plaque-forming units (PFU per ml) were calculated.
2.7. Capsid Precipitation. Following phage-PICI induction,
1ml was taken from each filtered lysate to then treat it with
DNase (1μgml-1 Sigma-Aldrich) and RNase (1μgml-1
Sigma-Aldrich) at room temperature for 30min. NaCl was
added to a final concentration of 0.5M, and samples were
incubated on ice for 1 h. After incubation, samples were
transferred into 2ml microfuge tubes containing 0.25 g of
PEG 8000 (Fisher Scientific) and incubated at 4°C overnight.
Samples were then centrifuged at 11,000 × g for 10min at
4°C. The supernatant was discarded and tubes were left to
dry for 5min. Pellets were then resuspended with 100μl of
phage buffer for 1 h. To lyse the capsids, 100μl of lysis buffer
(90μl H2O, 9.5μl SDS 20% CaCl2 Fisher Scientific, 4.5μl pro-
teinase K 20mgml-1 Sigma-Aldrich) was added, and samples
were incubated at 55°C for 30min. DNA extraction was then
performed by phenol-chloroform extraction and ethanol
precipitation. Finally, pellets were resuspended in 75μl of
MilliQ grade H2O to then be processed for southern blot.
2.8. Southern Blot. Phage-capsid bulk DNA and SaPI-capsid
DNA were separated by agarose gel electrophoresis by run-
ning samples on 0.7% agarose gel at 30V, overnight. The
DNA was transferred to Nylon membranes (Hybond-N
0.45mm pore size filters; Amersham Life Science) using stan-
dard methods. DNA was detected using a DIG-labeled probe
(Digoxigenin-11-dUTP alkali-labile; Roche) and anti-DIG
antibody (Anti-Digoxigenin-AP Fab fragments; Roche),
before washing and visualization. The primers used to obtain
the DIG-labeled probes are listed in Table S3.
2.9. SaPI Interference. An overnight culture of RN4220 recip-
ient strains containing the SaPIbov1 variants (strains JP1996,
JP20777 to JP20783) were diluted 1 : 50 with fresh medium
and grown until 0.3-0.4 OD540 or OD600. In a sterile test tube,
250μl of the recipient cells was added with 8ml of Phage Top
Agar (PTA) (20 g l-1 nutrient broth n°2, Oxoid; 3.5 g l-1 agar;
10mM CaCl2 Fisher Scientific) and immediately poured over
the surface of a Phage Base Plate (PB) (20 g l-1 nutrient broth
n°2, Oxoid; 7 g l-1 agar; 10mMCaCl2 Fisher Scientific). When
the top agar was solidified after 15-20min, the plates were
flipped and 10μl of serial dilutions of phage lysate obtained
from strains RN10616 and RN451 was spotted onto the
solidified lawn. The PBA plates were left at room temperature
to dry before being incubated at 37°C for 24h. The number of
plaques formed was counted, and the plaque-forming units
(PFU) were calculated.
2.10. Killing and Plasmid Curing Assays. A 1 : 50 dilution of
an overnight culture was prepared and grown until 1.0
OD600 was reached (approx. 4 × 108 CFU ml-1 for S aureus
and 8 × 108 CFU ml-1 for E. coli). Cultures were then diluted
to obtain a cell density of ~105CFUml-1. For the rebooted
SaPIbov2 versions with CRISPR-Cas9 (JP20279, JP20280,
JP21058, and JP21059), titers were normalized to ~106 TFU
ml-1 to use anMOI of 10. For killing assays, infected S. aureus
cells were plated on TSA with tetracycline to observe directly
the killing effect of strains containing the target. For plasmid
curing, cells were plated on TSA with tetracycline to measure
the proportion of cells transduced with the synthetic SaPI-
bov2 and on TSA containing both tetracycline and erythro-
mycin to measure the proportion of cells cured of pCN51
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with and without the target (JP13894 and JP17110). For the
rebooted EcCFT073 island containing CRISPR-Cas9 (strains
JP20690 and JP20691), titers were normalized to ~106 TFU
ml-1 to use a MOI of 10. E. coli cells were plated either on
LB with chloramphenicol to measure the proportion of cells
transduced with the synthetic PICI or on LB containing both
chloramphenicol and tetracycline to measure the proportion
of cells cured of pRIC with and without the target (JP17120
and JP17462).
To examine the curing of the plasmids by Cas9
deployment and activity, the ratio of resistance conferred
by plasmids to total transductants was calculated using the
number of TFUs of each sample over the number of TFUs
from cells carrying the control plasmid and transduced with
PICIs containing a Cas9-∅ array.
2.11. Quantification and Statistical Analysis. All statistical
analyses were performed as indicated in the figure legends
using the GraphPad Prism 6.01 software, where “n” repre-
sents the number of independent experiments.
3. Results
3.1. Assembly and Rebooting of Synthetic SaPIs. Since SaPIs
are the prototypical and best-characterized members of the
PICI family, they were used as our first model to test the
assembly of synthetic variants in yeast. As a proof of concept,
we tried to assemble and reboot the parent SaPIbov1
tst::tetM, which has been extensively used to study the biol-
ogy of these elements [18, 28–31]. Note that this SaPI carries
a tetracycline resistance cassette (tetM) inserted into the toxic
shock syndrome gene (tst), which facilitates our studies.
Primers with homology overhangs of ≥30 bp were
designed to amplify SaPIbov1 (Figures 1 and S1). Since this
SaPI is ~15 kb in size, 3 different PCR fragments were
designed to amplify the entire element. Each region was cho-
sen according to their function in the SaPI cycle [1]. Region 1
contained the SaPI regulatory and replication modules,
region 2 contained the interference and packaging modules,
while region 3 contained the accessory (virulence) module.
Thus, the use of these regions will allow us to generate in
the future chimeric and new SaPI variants. The 5′ region of
the first fragment and the 3′ region of the last fragment car-
ried homology overhangs with the YAC (pAUR112) frag-
ment containing the essential genes for selection and
assembly in yeast. Using the method described here, all three
SaPIbov1 tst::tetM and YAC fragments were transformed
into S. cerevisiae BJ5464 cells to assemble the synthetic SaPI
genome. Colonies of S. cerevisiae were restreaked and ana-
lyzed by colony PCR to confirm the presence of SaPIbov1.
For the PCR experiments, we used primers that amplify
and detect the recombination region of each two adjoining
fragments. Moreover, the presence of the first and last frag-
ments in the YAC was confirmed using external primers to
the YAC recombination sites together with fragment-
specific primers. Next, the YAC::SaPIbov1 tst::tetM DNA
was purified, electroporated into competent S. aureus
RN4220 cells, and the transformed cells grown onto TSA
plates containing tetracycline. After transformation with the
YAC::SaPIbov1 tst::tetM DNA, and in support of our initial
idea, tetracycline-resistant S. aureus colonies were detected,
suggesting SaPIbov1 tst::tetM was able to excise from the
YAC and integrate into the bacterial chromosome. The pres-
ence of the entire SaPIbov1 tst::tetM element was confirmed
by colony PCR employing primers that bind internally and
externally to the SaPI attC sites to verify integration (See
Table S3).
To confirm the functionality of the synthetic element, a
strain carrying the engineered SaPIbov1 tst::tetMwas lysoge-
nized with phage 80α, which activates the SaPIbov1 excision-
replication-packaging cycle [30]. The strain was induced
with mitomycin C (MC), and the phage and SaPI titers were
determined and compared to those obtained with the lyso-
genic strain for phage 80α harboring the original SaPIbov1
tst::tetM. Both islands were indistinguishable in their ability:
(i) to replicate after phage 80α induction (Figure 2(a)), (ii)
to be packaged and transferred to a new recipient strain
(Figures 2(b) and 2(c)), and (iii) to block phage reproduction
(Figures 2(d) and 2(e)), validating our strategy and confirm-
ing that no deleterious mutations arose during the assembly
or rebooting processes.
We next tested the ability of this method to generate
single, double, or even triple simultaneous mutations in
SaPIbov1 tst::tetM. Specifically, we generated a SaPIbov1
tst::tetM carrying a mutation in terS (JP20779), one carry-
ing a double mutation in ppi and cpmA (JP20781), and a
final one carrying a triple mutation in terS, ppi, and cpmA
(JP20783). The terS, ppi, and cpmA genes were selected
because they have defined roles in the SaPI life cycle: the
SaPI-encoded TerS protein is required for specific SaPI pack-
aging [32], Ppi binds to the phage-encoded TerS protein
blocking phage packaging [11], while CpmA expression is
required for the production of the small SaPI sized capsids
[32, 33]. Figure S2 shows the strategy used to generate the
different synthetic PICIs carrying the mutations of interest.
Overlapping PCR fragments were produced to introduce
two amber stop codons followed by a restriction site (for
screening). Using classic approaches, the generation of a
triple SaPIbov1 tst::tetM mutant would be highly time-
consuming (several months), requiring several rounds of
cloning and mutagenesis. In contrast, if functional, this
synthetic biology strategy will allow the production of several
mutations in one week.
All SaPIbov1 tst::tetMmutants were readily assembled in
yeast (strains JP20109, JP20733, JP20735, and JP20737) and
mobilized into S. aureus. Next, the different SaPIbov1-
positive cells were lysogenized with phages 80α (strains
JP21212-JP21215) and ϕ11 (strains JP21216-JP21219), and
the SaPI cycle analyzed after induction of the prophages with
MC. Thus, while all the islands replicate as the original SaPI-
bov1 tst::tetM (Figure 2(a)), the transfer of the elements car-
rying a mutation in the SaPI terS gene was significantly
reduced relative to that observed for the original island, and
to the same level as that observed for the previously charac-
terized SaPIbov1 tst::tetM terS mutant [32] (Figures 2(c)
and 2(d)). Moreover, the islands carrying the mutation in
the cpmA gene were unable to generate SaPI-sized (small)
capsids (Figures 2(a) and 2(b)), while the SaPIs carrying the
5BioDesign Research
80α
WT WT
)b()a(
)d()c(
)f()e(
terS⁎ ppi⁎
cpmA⁎
ppi⁎
cpmA⁎
terS⁎
terS⁎ ppi⁎
cpmA⁎
ppi⁎
cpmA⁎
terS⁎
Phage sized capsids
SaPI sized capsids
Phage sized capsids
SaPI sized capsids
ØP RB RB RB RB P RB RB RB RB
WT WT
Phage sized capsids
SaPI sized capsids
Phage sized capsids
SaPI sized capsids
Ф11
Ø
ns
ns
ns
ns
80α SaPIbov1 tst::tetM 
Pa
re
nt
W
T
te
rS
⁎
pp
i⁎
 cp
m
A
⁎
 te
rS
⁎
pp
i⁎
 cp
m
A
⁎
(–
)
Pa
re
nt
W
T
te
rS
⁎
pp
i⁎
 cp
m
A
⁎
 te
rS
⁎
pp
i⁎
 cp
m
A
⁎
(–
)
PF
U
 m
l–1
TF
U
 m
l–1
PF
U
 m
l–
1
TF
U
 m
l–
1
Phage titre
SaPI titre
Φ11 SaPIbov1 tst::tetM Φ11
⁎⁎⁎⁎
Phage titre
SaPI titre
ns ns
80
−
Parent
SaPIbov1 tst::tetM 
Rebooted
SaPIbov1 tst::tetM 
SaPIbov1 tst::tetM 
terS⁎
SaPIbov1 tst::tetM 
ppi⁎ cpmA⁎
SaPIbov1 tst::tetM 
ppi⁎ cpmA⁎ terS⁎
Parent
SaPIbov1 tst::tetM 
Rebooted
SaPIbov1 tst::tetM 
SaPIbov1 tst::tetM 
terS⁎
SaPIbov1 tst::tetM 
ppi⁎ cpmA⁎
SaPIbov1 tst::tetM 
ppi⁎ cpmA⁎ terS⁎
–
Φ11
80α
⁎⁎⁎⁎
⁎⁎⁎⁎
⁎⁎⁎⁎ ⁎⁎⁎⁎
⁎
⁎⁎⁎⁎ ⁎⁎⁎⁎
⁎⁎ ⁎⁎⁎ ⁎⁎⁎
⁎⁎⁎⁎
Figure 2: Effects of phage packaging and SaPI transfer on SaPIbov1 engineered mutations. Upper panel: The 80α (a) or ϕ11 (b) mediated
induction, replication, and packaging of the islands was analyzed by analysis of the DNA extracted from the purified SaPI and phage
lysates. In these experiments, two bands are observed, corresponding to the phage-sized or SaPI-sized capsids. The lower panel is a
Southern blot using a probe for the SaPIbov1 tetM cassette. Sample P represents the parent strain containing the helper phage and
SaPIbov1 tst::tetM while samples RB represent the rebooted versions of SaPIbov1 WT, SaPIbov1 terS∗, SaPIbov1 ppi∗cpmA∗, and
SaPIbov1 ppi∗cpmA∗terS∗. Null (∅) represents a lysate generated from a strain containing only the helper phage as a control.
(c, d) The lysates of each SaPIbov1 version obtained after induction of the helper phages 80α (c) or ϕ11 (d) were analyzed for phage titer
(PFU ml-1) and SaPIbov1 transduction titer (TFU ml-1), using RN4220 as recipient strain. The SaPIbov1-mediated phage interference was
tested by infecting strains containing the different SaPIbov1 derivative islands with lysates of phage (e) 80α or (f) ϕ11. Statistical analysis
was performed using two-way ANOVA followed by Dunnett’s multiple comparisons test with the parent strain 80α SaPIbov1 tst::tetM or
ϕ11 SaPIbov1 tst::tetM as controls and as reference for all comparisons, respectively (n = 6 ± SD). Adjusted p values for phage titers
using helper phage 80α, WT ns p = 0:9998, terS∗ ns p = 0:5386, ppi∗cpmA∗∗∗p = 0:0071, ppi∗cpmA∗terS∗∗∗∗p = 0:0007 and (-) ∗∗∗p = 0:0008;
and for SaPI titers WT ns p = 0:9997, terS∗∗∗∗∗p < 0:0001, ppi∗cpmA∗ ns p = 0:7993, ppi∗cpmA∗terS∗∗∗∗∗p < 0:0001. Adjusted p
values for phage titers using helper phage ϕ11, WT ns p = 0:9611, terS∗∗∗∗∗p < 0:0001, ppi∗cpmA∗∗∗∗∗p < 0:0001, ppi∗cpmA∗terS∗
∗∗∗∗p < 0:0001 and (-) ∗∗∗∗p < 0:0001; and for SaPI titers WT ns p = 0:4029, terS∗∗∗∗∗p < 0:0001, ppi∗cpmA∗∗p = 0:0283, ppi∗cpmA∗terS∗
∗∗∗∗p < 0:0001.
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double ppi/cpmA mutation were unable to interfere with the
reproduction of phages 80α and ϕ11 (Figures 2(e) and 2(f)).
For phage ϕ11, smaller plaques were observed compared to
the reproduction of phage ϕ11 on a lawn of RN4220, sug-
gesting that the other mechanisms of interference still have
an effect on the reproduction of this phage [33]. When
inducing the double (ppi/cpmA) or the triple (ppi/cpmA/-
terS) SaPIbov1 mutants, the phage titers were identical to
that observed after induction of helper phages 80α and
ϕ11 from a SaPIbov1-negative strain. Taken together, our
results confirm that SaPI assembly in yeast is an extraordi-
nary and easy method to gain insights into the biology of
these elements.
3.2. Assembly and Rebooting of Engineered SaPIs. As previ-
ously mentioned, SaPIs have been recently proposed as an
alternative to phages and antibiotics to combat S. aureus
infections [15]. Due to their easy assembly in yeast and their
high transferability in vivo, our method renders rapid engi-
neering of synthetic SaPIs carrying different markers and
antimicrobial payloads feasible. As a proof of concept, we
therefore constructed several synthetic SaPIs carrying an
antimicrobial payload (the CRISPR-Cas9 system [34, 35])
targeting either the methicillin resistance gene mecA or the
conserved small regulatory RNA rsaE [36–38], to eliminate
S. aureus cells (strains JP21059 and JP20282). As a control,
we also generated a synthetic SaPI carrying the CRISPR-
Cas9 system but no spacers against the mecA or rsaE genes
(strains JP21058 and JP20281, respectively). SaPIbov2 was
used here as scaffolding SaPI since it does not produce small
SaPI capsids [39] and therefore, synthetic derivative SaPIs
with an increased size (up to 45 kb, the size of the helper
phage) can be efficiently packaged and transferred. Following
the same workflow, we assembled SaPIbov2 with the two
aforementioned cargos (see scheme in Figure S3). After
their assembly in yeast, the synthetic SaPIs were rebooted
into S. aureus lysogenic for the phage 80α ΔterS mutant
(JP12871). This recipient strain was used since after the
induction of the mutant phage, the lysate will only contain
engineered SaPIbov2 particles, but no phage particles [8, 29]
(Figure 3(a)). We then proceeded to test the transduction
rates of the engineered elements as well as the activity of
the synthetic genes allocated in the adaptable module of
SaPIbov2. When we used S. aureus RN4220 as a recipient
strain, the transduction observed for the synthetic SaPIbov2
versions carrying either the CRISPR-Cas9 system with no
spacers or with the gRNA targeting mecA was identical to
that observed with a SaPIbov2 bap::tetM lysate (Figure 3(b)).
Remarkably, very few transductants were obtained for the
synthetic island carrying the inducible CRISPR-Cas9 system
targeting rsaE, confirming the engineered island was able
to kill S. aureus (Figures 3(c) and 3(d)). This was further
confirmed using as recipient S. aureus RN4220 cells in which
the targeted rsaE gene was removed (JP20283). Using these
cells, the transfer of all the CRISPR-Cas9-containing island
was identical to that observed for the SaPIbov2 bap::tetM
(Figures 3(b) and S4).
The synthetic SaPI carrying the CRISPR-Cas9 targeting
mecA was tested in two different scenarios: firstly, we tested
its ability to cure a RN4220 derivative strain carrying a
high-copy plasmid containing the cloned mecA resistance
gene (strains JP17110) (Figure S5). Next, and having
confirmed the activity of this island against this plasmid, we
tested the ability of this synthetic island to kill MRSA
strains. To this end, we used the MRSA USA100 and
USA200 strains as recipients in this experiment (strains
JP7581 and JP7593, respectively). As had previously occurred,
the transduction of the synthetic SaPIbov2 targeting mecA
was reduced 1000-fold in S. aureus USA100 and USA200
compared with RN4220 (Figures 3(e) and 3(f)), confirming
that the CRISPR-Cas9 system present in the modified
island was able to detect the target, cleave the double-
stranded DNA, and trigger cell death.
Finally, we created SaPIbov2 derivatives carrying
reporter genes (gfpmut2 or β-galactosidase (bgaB) (strains
JP21056 and JP21057, respectively; see scheme in
Figure S3) that would enable the use of PICIs as biosensors
for bacterial diagnostics. The transfer of these islands by the
80α helper phage was undistinguishable to that observed
for SaPIbov2 bap::tetM (Figure S6). Next, we tested the
functionality of the reporter genes present in the synthetic
islands. Plates exposed with Coomassie blue or fluorescein
filter showed that all colonies carrying the SaPIbov2::tetM-
gfpmut2 island expressed GFP, whilst the control colonies
carrying the wt SaPIbov2 bap::tetM did not show any
fluorescence (Figure 4(a)). Similar results were obtained
with the synthetic SaPIbov2 carrying the bgaB gene. Thus,
all the colonies were blue when grown in plates containing
X-gal, while the control colonies carrying the wt SaPIbov2
bap::tetM island were white (Figure 4(b)). These SaPIbov2
variants used to express reporters can be further modified
using specific promoters to act as biosensors for the
detection of a specific genetic trait after infection. Taken
together, these results validate our strategy for designing
and rapidly rebooting SaPIs with diverse cargos that can be
implemented for novel biotechnological purposes.
3.3. Assembly and Rebooting of Non-SaPI PICIs. Having
assembled and rebooted different SaPIs, we sought to know
whether this approach could be universalized as a strategy
to assemble and reboot other PICIs. Following the strategy
depicted in Figure 1, we tested whether it was possible
to assemble in yeast the EcCICFT073 element from E. coli
[3, 12]. Using three PCR fragments that covered the full
EcCICFT073 element (including >500 bp of the chromo-
somal flanking sequence), we rebooted this PICI by trans-
forming the YAC directly into E. coli strains C600 or 594.
As E. coli is more readily transformable compared to S.
aureus, the transformation of YAC-EcCICFT073 into E. coli
gave rise to a significantly higher number of colonies per
DNA unit (Figure S7). Next, we lysogenized the E. coli cells
with the EcCICFT073 helper phages λ or ϕ80 [3, 12]. The
resident prophages were induced with MC, and the cycle of
the synthetic EcCICFT073 element analyzed. As shown in
Figure S7, the transduction levels of the engineered element
were indistinguishable from those observed for the wt PICI.
In parallel to this, we rebooted another Gram-positive PICI,
SaPIpT1028 into S. aureus (JP12871) to show that this
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Figure 3: Engineered SaPIs with CRISPR-Cas9 for targeted therapy. (a) The synthetic SaPI exploits the packaging machinery of its temperate
phage to pack and deliver a CRISPR-Cas9 (black arrow) cargo into other bacteria. After induction with MC and activation of the ERP cycle,
both phage (light green) and SaPI (grey) excise from the bacterial (red) chromosome to be packed into viral particles. Only the SaPI-DNA is
packed with its cognate TerS (green arrow) and the TerL of the phage, while the phage-DNA packaging is disabled due to the deletion of the
phage TerS (black cross). Then, the cell is lysed and a lysate containing SaPI-only particles is generated. These viral particles containing the
synthetic SaPI with CRISPR-Cas9 cargo can be then deployed as antimicrobial elements to target and eliminate bacteria with the mecA
sequence (yellow arrow). (b) All of the synthetic SaPIbov2 variants except the synthetic island with CRISPR-Cas9 targeting rsaE showed
levels of transduction equal to the parent version induced under a background of packaging defective 80α ΔterS. Graphs represent
transduction titers performed in RN4220. Statistical analysis was performed using two-way ANOVA followed by Dunnett’s multiple
comparisons test using the parent SaPIbov2 bap::tetM as control and as reference for all comparisons (n = 4 ± SD). Adjusted p
values for rebooted SaPIbov2 bap::tetM p = 0:9976, SaPIbov2::tetM-cas9-∅ p = 0:0846, SaPIbov2::tetM-cas9-mecA p = 0:0745,
SaPIbov2::Pcad-cas9-∅-tetM p = 0:0846, and SaPIbov2::Pcad-cas9-rsaE-tetM ∗∗∗∗p < 0:0001. (c) A SaPIbov2 engineered with cadmium-
inducible CRISPR-Cas9 system targeting rsaE was used to kill S. aureus. RN4220. RN4220 ΔrsaE strain was used as control to show
specific killing by target. Cadmium concentrations were used at 1 μM. (d) Graphs represent transduction titers performed in RN4220.
Statistical analysis was performed using two-way ANOVA followed by Dunnett’s multiple comparisons test using infection with SaPIbov2
bap::tetM as control for each strain and as reference for all comparisons (n = 3 ± SD). Adjusted p values for infection of RN4220 ΔrsaE
with SaPIbov2::Pcad-cas9-∅-tetM p = 0:7317, and SaPIbov2::Pcad-cas9-rsaE-tetM p = 0:8916; and for infection of RN4220 with
SaPIbov2::Pcad-cas9-∅-tetM p = 0:7248, and SaPIbov2::Pcad-cas9-rsaE-tetM ∗∗∗∗p < 0:0001. (e) Killing of methicillin-resistant S. aureus
USA100 and USA200 was performed by using synthetic SaPIbov2::tetM-cas9 containing CRISPR-Cas9 targeting mecA. A SaPIbov2::tetM-
cas9 version with null (∅) gRNA was used as control. (f) Graphs represent transduction titers performed in MRSA strains. Statistical analysis
was performed using two-way ANOVA followed by Dunnett’s multiple comparisons test using infection with SaPIbov2 bap::tetM as control
for each strain and as reference for all comparisons (n = 3 ± SD). Adjusted p values for infection of RN4220 with SaPIbov2::tetM-cas9-∅ p =
0:9490, and SaPIbov2::tetM-cas9-mecA p = 0:8988; for infection of USA100 with SaPIbov2::tetM-cas9-∅ p = 0:8631, and SaPIbov2::tetM-
cas9-mecA ∗∗∗∗p < 0:0001; for infection of USA200 with SaPIbov2::tetM-cas9-∅ p = 0:9980, and SaPIbov2::tetM-cas9-mecA ∗∗∗∗p < 0:0001.
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technique can be employed to reboot other noncharacterized
SaPI elements.
Finally, following our approach to develop synthetic
SaPIs that can be used as Trojan horses to kill pathogenic
bacteria, we also incorporated a CRISPR-Cas9 system that
was previously employed to cure plasmids that confer antibi-
otic resistance in E. coli [27, 40] by targeting the New Delhi
metallo-β-lactamase (NDM-1) gene. We tested the trans-
duction and activity of the synthetic EcCICFT073 island
producing Cas9 (strains JP20690 and JP20691) against
cells carrying a plasmid with the Cas9-targeted sequence
(JP17462) (Figure 5). To avoid the killing effect that could
be produced by the helper phage, in this case, we transformed
the YAC-EcCICFT073-Cas9 element into E. coli cells lyso-
genic for the phage ϕ80 Δcos mutant (strain JP17091). Since
this prophage does not contain its cognate cos site, required
for phage packaging, induction of this prophage produces a
lysate that uniquely contains engineered EcCICFT073 ele-
ments (Figure 5(a)). As shown in Figure 5(c), the transfer
of the synthetic EcCICFT073-Cas9 element removed the
antibiotic resistance-conferring plasmid from the E. coli cells,
confirming the efficiency of the synthetic EcCICFT073-Cas9
element and validating the strategy to use yeast to assemble
and reboot synthetic PICIs.
4. Discussion
In this report, we have adapted a yeast-based platform for
phage engineering to produce PICI elements a la carte with
mutations and synthetic circuits. The current methods for
genome engineering of these mobile genetic elements
(MGEs) are laborious and can only produce a single muta-
tion or knock-in at a time. Traditionally, the manipulation
of SaPIs and other Gram-positive PICIs would be facilitated
by allelic exchange [17, 24] or CRISPR-based methods [41–
43] which have low frequencies of success and require several
steps of screening in order to achieve the desired modifica-
tion. In multiple cases, mutations may occur from sequences
that are highly variable, and therefore, can generate frame-
shifts or stop codons of no interest. For manipulation of the
Gram-negative PICIs, a λ red recombination system can be
employed to create single mutations or deletions [16, 44].
However, this technique requires a strong selection marker
and, in some cases, counterselection cannot be easily achieved
because the element may already contain such a marker to
track its transfer. Other methods, such as multiplex auto-
mated genome engineering (MAGE), could also be used for
PICI engineering. However, MAGE relies heavily on the
efficiency of the lambda recombinases, which works well in
E. coli and a few Gram-negative bacteria [45, 46], but has
not been validated in other bacterial. Surely, some recombi-
nases could be employed for a similar application in S. aureus
and other Gram-positive bacteria; however, our method can
be applied as a generic platform that is independent of phage
or host recombinases and only depends on the PICI being
assembled and its own integration efficiency. An additional
disadvantage of MAGE is that its efficiency diminishes sub-
stantially when attempting to introduce larger synthetic cir-
cuits (such as CRISPR-Cas9) from a single PCR product
into the PICI. Moreover, assembling PICIs in yeast allows
easy verification of the mutations prior to rebooting, and
direct rebooting of PICIs in the host cells offers complete
freedom for design and editing, including the incorporation
of different modifications and elimination of any undesired
features such as virulence factors, in a single assembly. Simi-
lar to the method employed by Ando et al. [20], we observed
that assemblies in yeast had high rates of success. Whole-
genome sequencing of strains JP20111, JP20117, JP20751,
and JP21056 confirmed that none of the rebooted PICIs
(SaPIbov1 tst::tetM, SaPIpT1028::ermC, SaPIbov2::tetM-
Pbla-gfpmut2, and SaPIbov2::tetM-cas9-mecA, respectively)
were different to the template during the reassembly and
rebooting process. Rebooting of the synthetic PICI DNA,
mirroring its structure when integrated in the host cell,
allowed us to avoid aberrant integrations in the yeast chro-
mosomes and enabled the efficient excision and circulariza-
tion of the element from the synthetic YAC and the
posterior integration of the functional PICI in the bacterial
chromosome. With high accuracy and reproducibility, this
method can be employed as a tool to systematically investi-
gate PICIs to comprehend their complex lifestyle.
SaPIbov2 ::tetM-gfpmut2SaPIbov2 bap::tetM
Bright field
Fluorescence
GFP – +
(a)
(b)
SaPIbov2 ::tetM-bgaBSaPIbov2 bap::tetM
Figure 4: GFP and Beta-gal reporter SaPIs (a) GFP-mediated
detection of S. aureus after infecting RN4220 cells with a lysates of
80α ΔterS SaPIbov2 tst::tetM and 80α ΔterS SaPIbov2::tetM-gfpmut2
using MOI of 10. (b) Blue-white screening in X-gal plates was
enabled by β-galactosidase expression in S. aureus RN4220 by
transduction of the SaPIbov2::tetM-bgaB into recipient cells of
RN4220. Cells transduced with SaPIbov2 bap::tetM were used as
control.
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Figure 5: Synthetic Gram-negative PICI used as targeted therapy. (a) The synthetic Gram-negative PICI exploits the packaging machinery of
its temperate phage to pack and deliver a CRISPR-Cas9 (black arrow) cargo into other bacteria. After induction with MC and activation of the
ERP cycle, both phage (light green) and PICI (grey) excise from the bacterial (orange) chromosome to be packed into viral particles. Only the
PICI-DNA is packed using the cos signaling (red block) to fulfil the viral particles hijacking the TerL of the phage with its cognate Rpp, while
the phage-DNA packaging is disabled due to deletion of the cosN site (black cross). Then, the cell is lysed and a lysate containing PICI-only
particles is generated. These viral particles containing the synthetic PICI with CRISPR-Cas9 cargo can be delivered as an antimicrobial
element, to target and cure plasmids (blue) carrying virulence or AMR genes (purple and yellow arrows). (b) The synthetic EcCICFT073
c1498-c1501::cas9 elements were designed by PCR fragments incorporating the CRISPR-Cas9 system in the adaptable module of the cos
island. (c) Deployment and activity of Synthetic PICI with CRISPR-cas9 system against plasmid pRIC carrying the ndm-1 gene. Graphs
represent the means of transduced cells with the chloramphenicol resistance cassette (cat) on tetracycline resistant cells (tetR) to measure
the proportion of cells cured of pRIC1 with the target gene by transduction of the PICI. Statistical analysis was performed using one-way
ANOVA followed by Tuckey’s multiple comparisons test (n = 3 ± SD). Adjusted p values for pRIC cas9-∅ versus pRIC cas9-ndm1 p =
0:729, pRIC cas9-∅ versus pRIC-ndm1 cas9-∅, p = 0:6147, pRIC cas9-∅ versus pRIC-NDM1 cas9-ndm1 ∗∗∗∗p < 0:0001, and pRIC cas9-
ndm1 versus pRIC-ndm1 cas9-ndm1 ∗∗∗∗p < 0:0001.
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We found that concentrations of the YAC-PICI DNA
extracted from yeast had similar yields to the commonly used
thermosensitive plasmids (pMAD, pBT2, pIMAY, etc.) for
allelic replacement. Similarly, the successful transforma-
tion of these plasmids is strictly dependent on the quality
of competent cells. In addition, rebooting Gram-negative
PICIs was much easier than rebooting Gram-positive PICIs
due to the efficiency of E. coli for acquiring plasmids
(Figure S8). In addition to using diverse protocols for making
electrocompetent cells, one can always opt to generate the
YAC-PICI with the necessary elements for transformation
in E. coli and then harvest a higher yield of DNA in order
to attempt the transformation of the PICI in its host.
Our approach to assemble synthetic versions of the
EcCICFT073 element not only demonstrates the engineering
of the first synthetic Gram-negative PICI but also shows the
incorporation of synthetic genes in a cos island, which needs
to maintain a genome size equal to exact fractions of their
helper phage genome (approx. 48 kb) (Figures 5(b) and 5(c)).
As shown by Ram et al. [15] and Kiga et al. [40], PICIs are
a very effective delivery system for antimicrobial payloads
because they possess higher frequency transfers than phage-
mids [27, 47, 48] and can be used to adapt larger modules
than phages [49], having almost two-thirds of the size to
spare for packaging DNA into the viral particles. Since PICIs
depend on the induction of helper phages, they are unable to
replicate and infect other bacteria after integration into the
host genome and can no longer actively participate in the dis-
semination of other MGEs. Thus, in contrast to phages used
to combat bacterial infections, PICIs on their own cannot
contribute to the spread of virulence traits. As proof of
principle, we employed two different constructs of the in
SaPIbov2, one with an inducible promoter targeting rsaE
and a constitutive promoter targeting mecA as options to
be applied in different clinical scenarios. A constitutive pro-
moter can be employed as a targeted therapy to directly treat
wound infections, while the inducible promoter can be used
as prophylaxis to efficiently eliminate bacteria complement-
ing the administration of antibiotics (i.e., catheters). Overall,
the applicability of PICIs as a tunable delivery system enables
the use of different CRISPR-Cas systems with diverse pro-
moters and the addition of other killing modules such as
toxins, quorum sensing inhibitors, and lysins. Another
advantage is that PICIs can use different helper phage chassis
as a strategy to expand their host range, making them the
perfect analogy of a Trojan horse to infiltrate and destroy
pathogenic bacteria. In addition, one can employ different
PICIs carrying diverse CRISPR arrays for a more efficient
PICI cocktail. Thereby, we consider these elements as a safer
platform for targeted antimicrobials compared to modified
phage-based applications. Although there is a promising field
to employ PICIs as a novel therapeutic approach, there are still
aspects to be assessed concerning the use of genetically modi-
fied PICIs and their interaction with other pathogenicity
islands found in clinical strains. In addition, to eliminate reg-
ulatory difficulties on their use as targeted therapy, PICIs with
the CRISPR-Cas system will need to be designed without any
antibiotic resistance cassette. In our experimental setting, the
presence of the antibiotic markers facilitated the readout of
the experiment, i.e., allowing us to identify the bacteria that
were infected with the synthetic PICIs carrying or not the
gRNA. However, this can be easily modified with our method.
Additionally, PICIs can be employed as an inexpensive
and simpler tool for bacterial detection without the need of
using DNA or RNA amplification, electrophoresis equipment,
or expensive optical devices, as only bacterial culture plates are
required. This approach benefits from the fact that the detec-
tion readout is produced by the pathogen itself, and its prepa-
ration requires little training. Reporter circuits in PICIs can be
designed with specific promoters that will trigger the signal as
a response to the expression of a specific gene related to bio-
film formation, virulence, or other pathogenic traits. A simple
portable device could be employed to detect bacteria infected
by our synthetic PICIs, carrying either a CRISPR-Cas13a sys-
tem [40] or different reporter genes, which might be observed
directly after a period of incubation, allowing the sequential
recovery of the pathogen for further investigation. Although
this further highlights the benefits of using PICI-based detec-
tion, there are still some limitations such as (i) bacterial growth
is required to use this approach; (ii) time will be required to
amplify the readout signal; and (iii) specific promoters will
be needed to differentiate between different bacterial strains.
In summary, our work shows that the rebooting of PICIs
can be used as a rapid method to study these MGEs. We
designed a strategy in which the PICIs are assembled in the
YAC mirroring the structure they have when they are inte-
grated into the bacterial chromosome to only promote their
rebooting in their cognate host. We created synthetic PICIs
with multiple mutations and adaptable modules in a faster
and elegant manner than allelic replacement, allowing us to
efficiently manipulate and reboot them in the host cells.
Using this method, we will continue unveiling the complex
biology and lifestyle of PICIs and their helper phages. We
hope our method can be used by different MGE communities
to systematically study them. Novel biotechnology approaches
could arise following this top-down approach to deconstruct
and manipulate viruses, to exploit them as a Trojan horse
against pathogens, and to provide advantages over antibiotics.
Additional Points
(i) An efficient and general method to generate and manipu-
late PICIs. (ii) Enable the study of PICIs by rapidly generat-
ing variants and mutations. (iii) Synthetic PICIs with
adaptable modules for different biotechnology applications.
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in this study. Table S3: oligonucleotides used in this study.
Figure S1: schematics of PCR fragments for PICI assembly
and process of excision and integration for rebooting.
Mirroring the structure of the integrated elements, amplifica-
tion of the first PCR fragment uses a forward primer that
binds >500 bp outside the attL site, whilst the last PCR frag-
ment uses a reverse primer that binds >500 bp outside the
attR site. The overlap region to the YAC is highlighted in
blue, and red represents the chromosome region before or
after the att sites. Internal fragments are amplified with
>30 bp overlaps to the adjacent PCR fragment (regions for
regulation, packaging, and toxins are represented in yellow,
green, and pink accordingly). Once the plasmid has been
transformed into the host cell, this undergoes excision, leav-
ing behind the YAC (blue) with the chromosomal region
(red). The PICI then integrates in the corresponding attB site
located in the genome. Figure S2: strategy used to generate
SaPIbov1 tst::tetM mutants. Multiple PCR fragments were
generated to introduce termination codons into ppi, cpmA,
and terS genes of SaPIbov1. Two amber stop codons were
introduced in the primer design followed by a restriction site
(XhoI, KpnI, and NotI accordingly) to identify the mutation
of each gene. PCR fragments were combined to assemble the
island with single, double, or triple mutations. Overlapping
regions to the YAC (blue), chromosome (red), SaPI regula-
tion module (yellow), packaging module (green), and toxin
module (pink) are highlighted in each PCR product used to
assemble the SaPI with mutations. Figure S3: design of syn-
thetic cargos for SaPIbov2. PCR fragments were produced
to maintain the essential genes for induction, replication,
and packaging (region 1 to 3) of the SaPIbov2 element. A
fragment containing the tetM cassette was used as region 4
to tract the transfer of the SaPI. Region 4 highlights the
adaptable module were different synthetic constructs can be
allocated in the island followed by the last fragment (region
5) containing the attR site to enable a successful integration
of the synthetic islands. Figure S4: transduction titers of SaPI-
bov2 ::Pcad-cas9-tetM. Lysates of 80α ΔterS SaPIbov2::Pcad-
cas9-tetM with and without gRNA against rsaE were titered
by infecting cultures of RN4220 and RN4220 ΔrsaE. Cells
with a concentration 1μM of CdCl2 were tested to further
induce the expression of the CRISPR-Cas9 system in the
island. Statistical analysis was performed using one-way
ANOVA followed by Tukey’s multiple comparisons test
(n = 3 ± SD). Adjusted p values for wt cas9-∅ versus wt
cas9-rsaE ∗∗∗p = 0:0003, ΔrsaE cas9-∅ versus ΔrsaE cas9-
rsaE ns p > 0:9999, wt cas9-∅ versus wt cas9-rsaE ∗∗∗∗p <
0:0001, and ΔrsaE cas9-∅ versus ΔrsaE cas9-rsaE ns p =
0:8846. Figure S5: curing of high copy plasmid pCN51 carry-
ing the mecA. Lysates of 80α ΔterS SaPIbov2::tetM-cas9 with
and without a gRNA targeting the methicillin resistance gene
mecA were assessed by infecting cultures of RN4220 carrying
either the pCN51 empty plasmid or the pCN51-mecA at a
cell density of ~105 CFU ml-1 for (MOI of 10). Recovered
cells were plated on TSA with erythromycin and tetracycline
to measure the proportion of cells cured of pCN51 with the
target. Statistical analysis was performed using one-way
ANOVA followed by Tukey’s multiple comparisons test
(n = 3 ± SD). Adjusted p values for pCN51 cas9-∅ versus
pCN51 cas9-mecA p = 0:9975, pCN51 cas9-∅ versus pCN51-
mecA cas9-∅, p = 0:9868, pCN51 cas9-∅ versus pCN51-mecA
cas9-mecA ∗∗∗∗p < 0:0001, and pCN51 cas9-mecA versus
pCN51-mecA cas9-mecA ∗∗∗∗p < 0:0001. Figure S6: transfer
of synthetic SaPIbov2 with reporters. The synthetic SaPIbov2
variants with reporters SaPIbov2::tetM-gfpmut2 and SaPI-
bov2::tetM-bgaB showed levels of transduction equal to the
parent version induced under a background of packaging
defective 80α. Statistical analysis was performed using two-
way ANOVA followed by Dunnett’s multiple comparisons
test (n = 3 ± SD ns p > 0:9999) with the parent strain 80α
ΔterS SaPIbov2 bap::tetM as control. Figure S7: assembly
and rebooting of non-SaPI PICIs. Assembly and rebooting
of non-SaPI PICIs. Transduction titers of rebooted PICIs
EcCICFT073 and SaPIpT1028 were compared to their wt
counterparts. The E. coli EcCICFT073 element was induced
and transferred using phages λ and ϕ80. The S. aureus ele-
ment SaPIpT1028 induced and packed by phage 80α ΔterS.
Graphs represent transduction titers performed on recipient
strains. Statistical analysis was performed using one-way
ANOVA followed by Tukey’s multiple comparisons test
(n = 4 ± SD). Adjusted p values for transduction titers of λ
EcCICFT073 wt (JP13413) versus rebooted (JP20123) p =
0:9994, ϕ80 EcCICFT073 wt (JP13410) versus rebooted
(JP20124) p = 0:8307, 80α ΔterS SaPIpT1028 wt (JP21184)
versus rebooted (JP210117) p > 0:9999. Figure S8: transfor-
mation efficiency of YAC-PICIs used in this study. Electro-
competent cells of S. aureus or E. coli were electroporated
with 2μg of YAC-PICI DNA assembled and extracted from
yeast. Graphs showed at least three independent replicates
from each transformation [3, 6, 12, 17, 23–27, 30, 40, 41,
48, 51–57]. (Supplementary Materials)
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